Unknown PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT01763658

Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia (ITP)

Evaluation of Oxidant Status in Patients With Immune Thrombocytopenia (ITP) and the Role of an Adjuvant Antioxidant Therapy

Sponsor: Ain Shams University

Conditions Immune Thrombocytopenia

Interventions Antox tablets(Mepaco) drug therapy for ITP

Updated 5 times since 2017 Last updated: Jan 8, 2013 Started: Mar 31, 2013 Primary completion: Sep 30, 2013 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Immune Thrombocytopenia and is currently ongoing. Ain Shams University leads this study, which shows 5 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2_PHASE3

First recorded

Mar 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ain Shams University

Data source: Ain Shams University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cairo, Egypt